WASHINGTON, D.C. 20549


                                    FORM 8-K

                                 CURRENT REPORT

                     PURSUANT TO SECTION 13 OR 15(D) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

       Date of report (Date of earliest event reported): February 24, 2005

                               CYTOGEN CORPORATION
               (Exact Name of Registrant as Specified in Charter)

          Delaware                       000-14879                22-2322400
----------------------------     ------------------------    -------------------
(State or Other Jurisdiction     (Commission File Number)     (I.R.S. Employer
      of Incorporation)                                      Identification No.)

650 College Road East, CN 5308, Suite 3100, Princeton, NJ            08540
---------------------------------------------------------       ----------------
        (Address of Principal Executive Offices)                   (Zip Code)

       Registrant's telephone number, including area code: (609) 750-8200

          (Former Name or Former Address, if Changed Since Last Report)

     Check the  appropriate  box below if the Form 8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

     |_|  Written communications  pursuant to Rule 425 under the  Securities Act
(17 CFR 230.425)

     |_|  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)

     |_|  Pre-commencement  communications  pursuant to Rule 14d-2(b)  under the
Exchange Act (17 CFR 240.14d-2(b))

     |_|  Pre-commencement  communications  pursuant to Rule 13e-4(c)  under the
Exchange Act (17 CFR 240.13e-4(c))


     As of February 24, 2005, Cytogen  Corporation (the "Company") and Progenics
Pharmaceuticals,  Inc.,  the owners of PSMA  Development  Company,  LLC, a joint
venture  formed  to  develop  in  vivo   immunotherapeutic   products  utilizing
prostate-specific  membrane antigen ("PSMA"), have not agreed on a work plan and
annual  budget for 2005.  The  parties are in the  process of  negotiating  such

     The joint  venture is funded by equal  capital  contributions  from each of
Progenics  and the Company in accordance  with an annual budget  approved by the
joint venture  representatives from each such party. The Company cannot give any
assurances that agreement will be reached on such matters in the near future, if
at all. The failure to reach  agreement  with  Progenics on these  matters could
significantly  and adversely  affect the  development of PSMA  technologies  and


     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                                CYTOGEN CORPORATION

                                                By:  /s/ Michael D. Becker
                                                   Michael D. Becker
                                                   President and Chief Executive

Dated:   February 24, 2005